According to market observers, unlisted shares of Shri Ahimsa Naturals Ltd are currently trading at Rs 135 apiece, which is a 13.45 per cent premium (GMP) over the issue price of Rs 119. Its listing ...

While Lilly's success with GLP-1 drugs is certainly impressive, I have my eyes on another area of the company this year. Let's dig into what Lilly's business looks like beyond weight loss ...

Eli Lilly is gearing up for a breakthrough in diabetes and obesity treatment with its upcoming oral GLP-1 drug, orforglipron. In an exclusive conversation with CNBC-TV18’s Shereen Bhan, the company’s ...

Health benefit consultants report a rise in demand for guidance on specialty drug and GLP-1 cost management. To meet this need, healthcare navigation and care coordination company Quantum Health ...

Novo Nordisk and the Chinese group’s wholly-owned subsidiary The United Bio-Technology have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, ...

Get Instant Summarized Text (Gist) A new drug delivery system attaches GLP-1 receptor agonists to antibodies within the body, enhancing diabetes and weight loss treatment. This method, tested in ...